Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5636567 | 0.98 | NOTUM (0.50) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| SCHEMBL5637075 | 0.92 | NOTUM (0.45) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5638604 | 0.90 | NOTUM (0.44) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| SCHEMBL161298 | 0.78 | NOTUM (0.38) | NOTUMKDM4EL3MBTL1GAAGSK3B | |
| Hydrochloric Acid SCHEMBL27645147 | 0.77 | NOTUM (0.37) | NOTUMKDM4EL3MBTL1GAAGSK3B | |
| SCHEMBL3969979 | 0.75 | NOTUM (0.56) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| SCHEMBL3969974 | 0.75 | NOTUM (0.51) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| SCHEMBL19157294 | 0.75 | NOTUM (0.51) | NOTUMKDM4ELMNAHPGDL3MBTL1 | |
| SCHEMBL3965007 | 0.75 | MAPT (0.52) | NOTUMKDM4ELMNAHDAC1HDAC6 | |
| SCHEMBL2361734 | 0.72 | NOTUM (0.53) | NOTUMKDM4ELMNAHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11066407-B2 | Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| CN-1370176-A | Subsstituted heterocycle fused gamma-carbolines | BRISTOL MYERS SQUIBB CO (US) | 2002-09-18 | — | — | CN | disclosed |
| US-5849731-A | Indole derivatives and medical application thereof | TORAY INDUSTRIES, INC. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0529452-B1 | 1,7-Condensed 3-(piperazinoalkyl)indol derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | SOLVAY PHARM GMBH (DE) | 1998-11-11 | — | — | EP | disclosed |
| CN-1165517-A | Indole derivatives and medical use thereof | TORAY INDUSTRIES (JP) | 1997-11-19 | — | — | CN | disclosed |
| EP-0805157-A1 | INDOLE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5324725-A | Antiinflammatory agent, antiallergen | KALI-CHEMIE PHARMA GMBH (DE) | 1994-06-28 | — | — | US | disclosed |
| US-5223625-A | Antagonistic acitivity on 5-hydroxytryptamine receptors | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1993-06-29 | — | — | US | disclosed |
| CN-1069732-A | 1, the 2-that 7-a pair of horses going side by side is closed (piperazine alkyl) indole derivatives and preparation method and intermediate product and the medicament that contains these compounds | KALI CHEMIE PHARMA GMBH (DE) | 1993-03-10 | — | — | CN | disclosed |
| EP-0529452-A2 | 1,7-Condensed 2-(piperazinoalkyl)indol derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | Kali-Chemie Pharma GmbH (DE) | 1993-03-03 | — | — | EP | disclosed |
| EP-0377238-A1 | New annelated indolo (3,2-c)-lactams | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NOTUM 3019/4885KDM4E 3461/4885LMNA 1958/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NOTUM 2986/4885KDM4E 3378/4885LMNA 2085/4885 |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | NOTUM 2685/4885KDM4E 597/4885LMNA 1196/4885 |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | NOTUM 2986/4885KDM4E 3378/4885LMNA 2085/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NOTUM 2986/4885KDM4E 3378/4885LMNA 2085/4885 |
| US-11066407-B2 | Preparation of certain substituted 1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | CYP2F1, CYP3A4, CYP4F2 | NOTUM 3694/4885KDM4E 1708/4885LMNA 3113/4885 |
| US-11407751-B2 | Hydrochloric acid salt of (6bR,10aS)-3-methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline | COX5B, IDH3B, CYP2J2 | NOTUM 4470/4885KDM4E 2282/4885LMNA 2504/4885 |
| US-12139490-B2 | Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one | CYP1B1, CYP4B1, CBR1 | NOTUM 2840/4885KDM4E 448/4885LMNA 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.